Skip to content
Try Mental Wellness – Lifestyle
Author:
Cloudbreak Pharma, Inc.
Cloudbreak Pharma Announces Top-Line Results from its Phase 3 Study of CBT-001 in Patients with Pterygium
November 4, 2026
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
June 4, 2026
Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum
May 12, 2026